Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease

Abstract

The emergence of SARS-CoV-2 has created an international health crisis, and small animal models mirroring SARS-CoV-2 human disease are essential for medical countermeasure (MCM) development. Mice are refractory to SARS-CoV-2 infection owing to low-affinity binding to the murine angiotensin-converting enzyme 2 (ACE2) protein. Here, we evaluated the pathogenesis of SARS-CoV-2 in male and female mice expressing the human ACE2 gene under the control of the keratin 18 promoter (K18). In contrast to nontransgenic mice, intranasal exposure of K18-hACE2 animals to 2 different doses of SARS-CoV-2 resulted in acute disease, including weight loss, lung injury, brain infection, and lethality. Vasculitis was the most prominent finding in the lungs of infected mice. Transcriptomic analysis from lungs of infected animals showed increases in transcripts involved in lung injury and inflammatory cytokines. In the low-dose challenge groups, there was a survival advantage in the female mice, with 60% surviving infection, whereas all male mice succumbed to disease. Male mice that succumbed to disease had higher levels of inflammatory transcripts compared with female mice. To our knowledge, this is the first highly lethal murine infection model for SARS-CoV-2 and should be valuable for the study of SARS-CoV-2 pathogenesis and for the assessment of MCMs.

References 53

1. 1.

   Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.

   Not in our library10.1016/s0140-6736(20)30211-7

2. 2.
   A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020

   No notice
3. 3.

   Yang X, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.

   Not in our library10.1016/s2213-2600(20)30079-5

4. 4.

   Barnes BJ, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652.

   Not in our library10.1084/jem.20200652

5. 5.

   Salimi S, Hamlyn JM. COVID-19 and crosstalk with the hallmarks of aging. J Gerontol A Biol Sci Med Sci. 2020;null(9):glaa149.

   Not in our library10.1093/gerona/glaa149

6. 6.
   The hallmarks of COVID-19 disease · 2020

   No notice
7. 7.

   Ackermann M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-128.

   Not in our library10.1056/nejmoa2015432

8. 8.

   Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20(7):389-391.

   Not in our library10.1038/s41577-020-0343-0

9. 9.

   Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-2040.

   Not in our library10.1182/blood.2020006000

10. 10.

    Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607-613.

    Not in our library10.1016/j.jinf.2020.03.037

11. 11.

    Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med. 2020;217(6):e20200678.

    Not in our library10.1084/jem.20200678

12. 12.

    DosSantos MF, et al. Neuromechanisms of SARS-CoV-2: a review. Front Neuroanat. 2020;14:37.

    Not in our library10.3389/fnana.2020.00037

13. 13.
    Early recovery following new onset anosmia during the COVID-19 pandemic – an observational cohort study · 2020

    No notice
14. 14.

    Natoli S, Oliveira V, Calabresi P, Maia LF, Pisani A. Does SARS-Cov-2 invade the brain? Translational lessons from animal models. Eur J Neurol. 2020;27(9):1764-1773.

    Not in our library10.1111/ene.14277

15. 15.

    Li W, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-454.

    Not in our library10.1038/nature02145

16. 16.

    Shang J, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221-224.

    Not in our library10.1038/s41586-020-2179-y

17. 17.

    Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.

    Not in our library10.1016/j.cell.2020.02.052

18. 18.

    Wrapp D, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-1263.

    Not in our library10.1126/science.abb2507

19. 19.

    Lan J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215-220.

    Not in our library10.1038/s41586-020-2180-5

20. 20.

    Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127-20.

    Not in our library10.1128/jvi.00127-20

21. 21.

    Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. Curr Opin Virol. 2015;13:123-129.

    Not in our library10.1016/j.coviro.2015.06.009

22. 22.

    Subbarao K, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol. 2004;78(7):3572-3577.

    Not in our library10.1128/jvi.78.7.3572-3577.2004

23. 23.

    Bao L, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature. 2020;583(7818):830-833.

    Not in our library10.1038/s41586-020-2312-y

24. 24.

    Glass WG, Subbarao K, Murphy B, Murphy PM. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol. 2004;173(6):4030-4039.

    Not in our library10.4049/jimmunol.173.6.4030

25. 25.
    SARS-CoV Pathogenesis Is Regulated by a STAT1 Dependent but a Type I, II and III Interferon Receptor Independent Mechanism · 2010

    No notice
26. 26.

    Hogan RJ, et al. Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J Virol. 2004;78(20):11416-11421.

    Not in our library10.1128/jvi.78.20.11416-11421.2004

27. 27.

    Lutz C, Maher L, Lee C, Kang W. COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice. Hum Genomics. 2020;14(1):20.

    Not in our library10.1186/s40246-020-00272-6

28. 28.

    Tseng CT, et al. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. J Virol. 2007;81(3):1162-1173.

    Not in our library10.1128/jvi.01702-06

29. 29.

    Yang XH, et al. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. Comp Med. 2007;57(5):450-459.

    Not in our library

30. 30.

    McCray PB, et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81(2):813-821.

    Not in our library10.1128/jvi.02012-06

31. 31.

    Menachery VD, et al. SARS-like WIV1-CoV poised for human emergence. Proc Natl Acad Sci U S A. 2016;113(11):3048-3053.

    Not in our library10.1073/pnas.1517719113

32. 32.

    Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82(15):7264-7275.

    Not in our library10.1128/jvi.00737-08

33. 33.

    Dinnon KH, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures [published online August 27, 2020]. Nature.

    Not in our library10.1038/s41586.020.2708-8

34. 34.

    Sun SH, et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe. 2020;28(1):124-133.e4.

    Not in our library10.1016/j.chom.2020.05.020

35. 35.

    Hassan AO, et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell. 2020;182(3):744-753.e4.

    Not in our library10.1016/j.cell.2020.06.011

36. 36.

    Israelow B, et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling. J Exp Med. 2020;217(12):e20201241.

    Not in our library10.1084/jem.20201241

37. 37.

    Yamaji-Kegan K, Su Q, Angelini DJ, Myers AC, Cheadle C, Johns RA. Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMalpha) increases lung inflammation and activates pulmonary microvascular endothelial cells via an IL-4-dependent mechanism. J Immunol. 2010;185(9):5539-5548.

    Not in our library10.4049/jimmunol.0904021

38. 38.

    Zhao Y, et al. Protection of LPS-induced murine acute lung injury by sphingosine-1-phosphate lyase suppression. Am J Respir Cell Mol Biol. 2011;45(2):426-435.

    Not in our library10.1165/rcmb.2010-0422oc

39. 39.

    Suryadevara V, et al. Sphingolipids in ventilator induced lung injury: role of sphingosine-1-phosphate lyase. Int J Mol Sci. 2018;19(1):114.

    Not in our library10.3390/ijms19010114

40. 40.

    Blanco-Melo D, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036-1045.

    Not in our library10.1016/j.cell.2020.04.026

Cited by papers we hold 9

• Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia · 2022
  No notice
• The cGAS–STING pathway drives type I IFN immunopathology in COVID-19 · 2022
  No notice
• Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model · 2021
  Not checked
• Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model · 2021
  Not checked
• Neuroinvasion and Encephalitis Following Intranasal Inoculation of SARS-CoV-2 in K18-hACE2 Mice · 2021
  No notice
• SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration · 2021
  No notice
• K18-hACE2 mice develop respiratory disease resembling severe COVID-19 · 2021
  No notice
• The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19 · 2021
  No notice
• Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.